Atropos Health and Every Cure team up to use generative AI to repurpose drugs

Every Cure will leverage GENEVA OS and data from the Atropos Evidence Network

Every Cure is a non-profit, founded by Dr. David Fajgenbaum following his brush with a near-fatal rare disease that doctors struggled to diagnose, that finds new uses for existing drugs. Atropos Health, meanwhile, was founded by Dr. Brigham Hyde to eliminate disparity in underserved populations via drug repurposing following his mother's battle with a rare blood cancer.

On Monday the two companies announced they are teaming up, forming a partnership which will allow Every Cure to leverage Atropos' generative AI platform, GENEVA OS, and data from the Atropos Evidence Network.

"By harnessing our proven AI-approach to analyze the world’s knowledge of drugs and diseases, Every Cure saves lives by repurposing existing drugs to treat diseases without cures. By focusing on impact in communities most in need rather than profit, we repurpose medicines already on the pharmacy shelf to save lives around the world for a fraction of the cost," Hyde told VatorNews.

Founded in 2020, Atropos' platform aggregates data from millions of patient charts so it can answer physician questions, and then generates a report, which it calls a Prognostogram. For example, if a pediatric cardiologist is seeing a new patient with an incidental diagnosis of atrial septal aneurysm, they might want to find out about the need for anticoagulation. However, the existing literature might not be helpful for a variety of reasons, either because a study answering the question hasn't been done yet, the available evidence is unreliable, or the evidence doesn't apply to their patient.

When a physician poses the question, which can be done through their EMR or from the company's online portal, it cleans up the data in the electronic health record and then uses a novel search engine to generate patient cohorts and perform statistical analyses to provide an answer. The Atropos team works with the physician to refine the question, perform the analysis, and to provide an interpretation of what the results mean for their patient. Atropos' clinicians will also discuss and clarify any follow-up questions. 

The Atropos Evidence Network includes de-identified medical records from over 200 million patients from over 10 years, globally. The data comes from a list of healthcare RWD sources, including from data platforms, aggregators, academic medical centers (AMCs), large health systems (IDNs), community oncology practices, and more.

In October, the company launched its Geneva OS and ChatRWD user application, the first Generative AI application incorporating direct chat-to-database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

"The launch of Geneva OS and ChatRWD has advanced research and development for healthcare and life sciences organizations across the US, allowing researchers and care providers to rapidly generate evidence upon simple request. In the next few years, Atropos aims to grow the Atropos Evidence Network to over 300 million records, allowing for better matchmaking of unanswered questions to the right data sources," Hyde said.

Every Cure, meanwhile, has developed an open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 20,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.

With this partnership, Every Cure will now have access to the Atropos Evidence Network to confirm and enhance their findings rapidly, allowing Every Cure to take a signal about the potential of new uses for a certain drug for a new indication coming from their AI platform. The company will also be able to leverage GENEVA OS and the Atropos Evidence Network to confirm that signal in real world patients. 

"The collaboration allows Every Cure to leverage GENEVA OS and data from the Atropos Evidence Network to confirm and enhance findings from their AI driven data platform in the real world. By doing this, it offers key real world signals and generation of AI model features to emulate the effect of therapies in real world populations. This rapid, high quality evidence generation dramatically accelerates the potential of yielding new uses for existing drugs and can accelerate clinical development by providing a real-world signal of patient response," said Hyde.

"We see a bright future for medicine and the use of evidence-based decisionmaking. By harnessing the power of user experience and automation, and democratizing information we believe we can affect change to create better patient outcomes. We believe the technology will revolutionize how patients are diagnosed and treated."

(Image source: atroposhealth.com)